Blood biomarker associated with prevalence, severity of Alzheimer's, but not risk of development
Higher levels in blood of the protein clusterin, also known as apolipoprotein J, are significantly associated with the prevalence and severity of Alzheimer's disease, but not with the risk of onset of new disease, according to a study in the April 6 issue of JAMA. Clusterin levels have been found to be increased in brain and cerebrospinal fluid of patients with Alzheimer disease (AD), and have been suggested to be involved in the pathogenesis of AD. "Plasma clusterin was reported to be associated with brain atrophy, baseline disease severity, and rapid clinical progression in AD, suggesting its possible use as a biomarker of AD," according to background information in the article.
Elisabeth M. C. Schrijvers, M.D., of Erasmus MC University Medical Center, Rotterdam, the Netherlands, and colleagues examined the associations between plasma levels of clusterin and the prevalence, severity, and risk of AD. The study included analysis of data on plasma levels of clusterin measured at baseline (1997-1999) in 60 individuals with prevalent AD, a random sub-group of 926 participants, and an additional 156 participants diagnosed with AD during follow-up (average, 7.2 years) until January 2007.
The researchers found that the likelihood of prevalent AD increased with increasing plasma levels of clusterin, with the odds increased by 63 percent for every standard deviation increase in clusterin levels, after adjusting for age, sex, education level, apolipoprotein E status, diabetes, smoking, coronary heart disease, and hypertension. Among patients with AD, higher clusterin levels were associated with more severe disease.
There was no statistically significant association of plasma clusterin levels with new AD during total follow-up or with new AD within or after 3 years of baseline. Results for all-cause dementia and vascular dementia were similar.
"In conclusion, our data from the general population show that increased plasma clusterin levels are associated with prevalent AD and are higher in more severe cases of AD. However, increased levels of clusterin do not precede development of AD and therefore are not a potential early marker of subclinical disease," the authors write.
Source: JAMA and Archives Journals
- Plasma protein appears to be associated with development and severity of Alzheimer's diseaseMon, 5 Jul 2010, 16:36:18 EDT
- High blood levels of vitamin E reduces risk of Alzheimer'sWed, 7 Jul 2010, 10:24:05 EDT
- Higher levels of protein hormone associated with lower risk of dementia, Alzheimer's diseaseTue, 15 Dec 2009, 19:54:10 EST
- Study evaluates association of genetic factors and brain imaging findings in Alzheimer's diseaseMon, 14 Jun 2010, 16:34:51 EDT
- Higher levels of compound in blood associated with lower risk of respiratory diseaseTue, 15 Feb 2011, 16:34:36 EST
- Blood biomarker associated with prevalence, severity of Alzheimer's, but not risk of developmentfrom Science CentricWed, 6 Apr 2011, 12:20:08 EDT
- Blood biomarker associated with prevalence, severity of Alzheimer's, but not risk of developmentfrom Science DailyTue, 5 Apr 2011, 17:30:21 EDT
- Blood biomarker associated with prevalence, severity of Alzheimer's, but not risk of developmentfrom PhysorgTue, 5 Apr 2011, 17:00:57 EDT
Latest Science NewsletterGet the latest and most popular science news articles of the week in your Inbox! It's free!
Check out our next project, Biology.Net
From other science news sites
Popular science news articles
No popular news yet
No popular news yet
No popular news yet
- Stem cell transplant restores memory, learning in mice
- 2 landmark studies report on success of using image-guided brachytherapy to treat cervical cancer
- Researchers discover mushrooms can provide as much vitamin D as supplements
- Cutting back on sleep harms blood vessel function and breathing control
- Study: Low-dose aspirin stymies proliferation of 2 breast cancer lines